Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas

References

• InGKHuJSTsengWWTreatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerationsTher Adv Med Oncol20179853355028794805
   PubMed Web of Science ®Google Scholar
• SiegelRLMillerKDJemalACancer statistics, 2017CA Cancer J Clin201767173028055103
   PubMed Web of Science ®Google Scholar
• BlayJYEl SayadiHThiessePGarretJRay-CoquardIComplete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)Ann Oncol200819482182218296418
   PubMed Web of Science ®Google Scholar
• CasaliPGZalcbergJLe CesneATen-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group intergroup phase III randomized trial on imatinib at two dose levelsJ Clin Oncol201735151713172028362562
   PubMed Web of Science ®Google Scholar
• DeVitoNHendersonEHanGClinical characteristics and outcomes for solitary fibrous tumor (SFT): a single center experiencePLoS One20151010e014036226469269
   PubMed Web of Science ®Google Scholar
• DufresneACassierPCouraudLDesmoplastic small round cell tumor: current management and recent findingsSarcoma2012201271498622550424
   PubMedGoogle Scholar
• KummarSAllenDMonksACediranib for metastatic alveolar soft part sarcomaJ Clin Oncol201331182296230223630200
   PubMed Web of Science ®Google Scholar
• RutkowskiPVan GlabbekeMRankinCJImatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trialsJ Clin Oncol201028101772177920194851
   PubMed Web of Science ®Google Scholar
• SchuetzeSMBolejackVChoyEPhase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumorCancer20171231909727696380
   PubMed Web of Science ®Google Scholar
• SethiTKKeedyVLHistology-specific uses of tyrosine kinase inhibitors in non-gastrointestinal stromal tumor sarcomasCurr Treat Options Oncol20161721126931561
   PubMed Web of Science ®Google Scholar
• StacchiottiSNegriTZaffaroniNSunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effectAnn Oncol20112271682169021242589
   PubMed Web of Science ®Google Scholar
• WagnerAJMalinowska-KolodziejIMorganJAClinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumorsJ Clin Oncol201028583584020048174
   PubMed Web of Science ®Google Scholar
• JudsonIVerweijJGelderblomHDoxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialLancet Oncol201415441542324618336
   PubMed Web of Science ®Google Scholar
• Le CesneAJudsonICrowtherDRandomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma GroupJ Clin Oncol200018142676268410894866
   PubMed Web of Science ®Google Scholar
• VermaSYounusJStys-NormanDHaynesAEBlacksteinMMembers of the Sarcoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based CareMeta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcomaCancer Treat Rev200834433934718313854
   PubMed Web of Science ®Google Scholar
• VermaSYounusJStys-NormanDHaynesAEBlacksteinMSarcoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-based CareDose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic reviewCancer200811261197120518224666
   PubMed Web of Science ®Google Scholar
• TapWDJonesRLVan TineBAOlaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trialLancet20163881004348849727291997
   PubMed Web of Science ®Google Scholar
• JudsonIRadfordJAHarrisMRandomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma GroupEur J Cancer200137787087711313175
   PubMed Web of Science ®Google Scholar
• SkubitzKMPhase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcomaJ Cancer Invest2003212167176
   PubMed Web of Science ®Google Scholar
• SleijferSSeynaeveCVerweijJUsing single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard careOncologist2005101083384116314294
   PubMed Web of Science ®Google Scholar
• ComandoneAPetrelliFBoglioneABarniSSalvage therapy in advanced adult soft tissue sarcoma: a systematic review and meta-analysis of randomized trialsOncologist201722121518152728835514
   PubMed Web of Science ®Google Scholar
• NoujaimJConstantinidouAMessiouCSuccessful ifosfamide rechallenge in soft-tissue sarcomaAm J Clin Oncol201841214715126523439
   PubMed Web of Science ®Google Scholar
• RosenGForscherCLowenbraunSSynovial sarcoma. Uniform response of metastases to high dose ifosfamideCancer19947310250625118174046
   PubMed Web of Science ®Google Scholar
• HensleyMLMakiRVenkatramanEGemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trialJ Clin Oncol200220122824283112065559
   PubMed Web of Science ®Google Scholar
• MakiRGWathenJKPatelSRRandomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]J Clin Oncol200725192755276317602081
   PubMed Web of Science ®Google Scholar
• PautierPFloquetAPenelNRandomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study)Oncologist20121791213122022907974
   PubMed Web of Science ®Google Scholar
• HensleyMLBlessingJADegeestKAbulafiaORosePGHomesleyHDFixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II studyGynecol Oncol2008109332332818394689
   PubMed Web of Science ®Google Scholar
• DemetriGDvon MehrenMJonesRLEfficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trialJ Clin Oncol201634878679326371143
   PubMed Web of Science ®Google Scholar
• van der GraafWTBlayJYChawlaSPPazopanib for metastatic soft-tissue sarcoma: a randomised, double-blind, placebo-controlled phase 3 trialLancet201237998291879188622595799
   PubMed Web of Science ®Google Scholar
• SchöffskiPChawlaSMakiRGEribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trialLancet2016387100281629163726874885
   PubMed Web of Science ®Google Scholar
• KratzFWarneckeAScheuermannKProbing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compoundJ Med Chem200245255523553312459020
   PubMed Web of Science ®Google Scholar
• MitaMMNataleRBWolinEMPharmacokinetic study of aldoxorubicin in patients with solid tumorsInvest New Drugs201533234134825388939
   PubMed Web of Science ®Google Scholar
• UngerCHäringBMedingerMPhase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicinClin Cancer Res200713164858486617699865
   PubMed Web of Science ®Google Scholar
• ChawlaSPChuaVSHendifarAFA phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcomaCancer2015121457057925312684
   PubMed Web of Science ®Google Scholar
• EilberFCSankhalaKKChawlaSPAdministration of aldoxorubicin and 14 days continuous infusion of ifosfamide/mesna in metastatic or locally advanced sarcomas [abstract]J Clin Oncol20173515_suppl11051
   Web of Science ®Google Scholar
• SankhalaKKChawlaSPChuaVSPhase Ib trial of combining aldoxorubicin plus doxorubicin [abstract]J Clin Oncol20133115_suppl2550
   Web of Science ®Google Scholar
• SankhalaKKChawlaSChuaVSPhase 1b study of aldoxorubicin + gemcitabine in metastatic solid tumors [abstract]J Clin Oncol20163415_suppl2523
   Web of Science ®Google Scholar
• ChawlaSPPapaiZMukhametshinaGFirst-line aldoxorubicin vs doxorubicin in metastatic or locally advanced unresectable soft-tissue sarcoma: a phase 2b randomized clinical trialJAMA Oncol2015191272128026378637
   PubMed Web of Science ®Google Scholar
• ParsonsCChawlaSDinhHTreatment of HIV-associated Kaposi’s sarcoma with aldoxorubicin [abstract]J Clin Oncol20153315_supple21526
   Web of Science ®Google Scholar
• ChawlaSPGanjooKNSchuetzeSPhase III study of aldoxorubicin vs investigators’ choice as treatment for relapsed/refractory soft tissue sarcomas [abstract]J Clin Oncol20173515_suppl11000
   Web of Science ®Google Scholar
• ChughRSchuetzeSMAldoxorubicin in sarcoma: teaching an old drug new tricksJAMA Oncol2015191280128126379207
   PubMed Web of Science ®Google Scholar
• LebrechtDGeistAKetelsenUPThe 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damageInt J Cancer2007120492793417131338
   PubMed Web of Science ®Google Scholar
• BoucekRJOlsonRDBrennerDEOgunbunmiEMInuiMFleischerSThe major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractionsJ Biol Chem198726215851158562890636
   PubMed Web of Science ®Google Scholar
• Del TaccaMDanesiRDucciMBernardiniCRomaniniAMight adriamycinol contribute to adriamycin-induced cardiotoxicity?Pharmacol Res Commun198517107310844089011
   PubMedGoogle Scholar
• ChawlaSPSankhalaKWielandSLevittDJLonger term cardiac safety of aldoxorubicin [abstract]J Clin Oncol20153315_suppl10546
   Web of Science ®Google Scholar
• Lyseng-WilliamsonKADugganSTKeatingGMPegylated liposomal doxorubicin: a guide to its use in various malignanciesBioDrugs201327553354024018470
   PubMed Web of Science ®Google Scholar
• PovedaALópez-PousaAMartínJPhase II clinical trial with pegylated liposomal doxorubicin (CAELYX(R)/Doxil(R)) and quality of life evaluation (EORTC QLQ-C30) in adult patients with advanced soft tissue sarcomas: a study of the Spanish Group for Research in SarcomasSarcoma200593–412713218521419
   PubMedGoogle Scholar
• ChidiacTBuddGTPelleyRPhase II trial of liposomal doxorubicin (Doxil®) in advanced soft tissue sarcomasInvest New Drugs20001825325910958594
   PubMed Web of Science ®Google Scholar